Roche
Roche’s skin cancer drug receives FDA priority review
November 9, 2011Research and Development, Sales and Marketing Roche, vismodegib
Roche’s skin cancer pill vismodegib will receive a priority review from the FDA which could see it approved within six …
Abbott spin-off could attract mega merger
October 21, 2011Research and Development, Sales and Marketing Abbott, Bayer, Humira, Merck, Roche
Abbott’s new spin-off pharma firm could attract a lot of attention from big pharma looking to sure up their portfolios. …
Injectable Herceptin proves its worth
October 20, 2011Research and Development, Sales and Marketing Herceptin, Roche
An injectable version of Roche’s breast cancer drug Herceptin compares favourably to the standard intravenous infusion, according to new research. …
Roche buys US firm Anadys for $230 million
October 17, 2011Research and Development, Sales and Marketing Roche, hepatitis C
Roche has acquired US firm Anadys for $230 million, bolstering its infectious drugs pipeline. California-based Anadys develops oral, small molecule …
Roche revenue drops as key products underperform
October 13, 2011Sales and Marketing Roche
Roche has posted worse-than-expected figures for the first nine months of this year after key products failed to shine and …
Manufacturing makes a comeback at Roche’s Nutley site
October 4, 2011Manufacturing and Production Roche, pharma manufacturing news
Roche has opened a new manufacturing facility at its campus in Nutley, New Jersey, that will supply dosage forms for …
Roche’s Herceptin successor impresses at EMCC
September 27, 2011Research and Development Herceptin, Roche, TDM-1
Roche’s next-generation breast cancer drug T-DM1 has impressed at the European cancer congress after besting Herceptin in a new study. …
Roche cleared over rep conduct complaint
September 23, 2011Sales and Marketing ABPI Code of Practice, Roche
Roche has been cleared by Code regulator the PMCPA of any wrongdoing after an NHS employee complained about the promotion …
Roche to show new cancer data at European congress
September 20, 2011Research and Development Cancer, Roche, T-DM1, Zelboraf, avastin
Roche will highlight a range of new approaches in targeting cancer at the upcoming European cancer conference. In a series …
Roche and Evotec to develop Alzheimer’s drug
September 6, 2011Alzheimer's disease, Evotec, Roche
Roche and Evotec are to collaborate on the development and commercialisation of Evotec’s MAO-B inhibitor in patients with Alzheimer’s disease. …
Tarceva approval for first-line use in EGFR lung cancer
September 1, 2011Sales and Marketing NSCLC, Roche, Tarceva
Tarceva has been granted final European approval for patients with a genetically distinct type of non-small cell lung cancer (NSCLC). …
Roche skin cancer drug approval ‘imminent’
August 11, 2011Sales and Marketing Roche, melanoma, vemurafenib
Skin cancer treatment Zelboraf looks set to gain FDA approval months ahead of schedule. Roche and Daiichi Sankyo’s drug is …
NICE wants more RoActemra data for juvenile idiopathic arthritis
August 9, 2011Medical Communications NICE, RoActemra, Roche
NICE has requested more evidence from Roche for RoActemra in childhood arthritis. RoActemra (tocilizumab) is being assessed for the treatment …
Investment firm adds Roche facility to growing portfolio
August 9, 2011Manufacturing and Production Colarado, International Chemical Investors, Roche, pharma manufacturing news
International Chemical Investors Group has snapped up another manufacturing facility, this time agreeing to buy a plant owned by Roche …
First personalised asthma drug shows promise
August 4, 2011Roche, asthma, personalised medicine
Roche’s personalised asthma drug lebrikizumab has met its primary end point in a phase II trial. Lebrikizumab increased the level …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
